Dipeptidyl Peptidase-1 Inhibition in Patients Hospitalized with COVID-19: a Multicentre Randomized Double-Blind Placebo Controlled Trial
H. Keir (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), H. Abo-Leyah (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), T. Vadiveloo (Aberdeen, United Kingdom), T. Pembridge (Dundee, United Kingdom), R. Hull (Sheffield, United Kingdom), L. Delgado (Dundee, United Kingdom), M. Band (Dundee, United Kingdom), F. Mclaren-Neil (Dundee, United Kingdom), S. Adamson (Dundee, United Kingdom), E. Lahnsteiner (Dundee, United Kingdom), A. Gilmour (Dundee, United Kingdom), C. Hughes (Dundee, United Kingdom), B. New (Dundee, United Kingdom), D. Connell (Dundee, United Kingdom), R. Dowey (Sheffield, United Kingdom), H. Turton (Sheffield, United Kingdom), H. Richardson (Dundee, United Kingdom), D. Cassidy (Dundee, United Kingdom), J. Cooper (Aberdeen, United Kingdom), J. Suntharalingam (Bath, United Kingdom), L. Diwakar (Stoke-on-Trent, United Kingdom), P. Russell (Harlow, United Kingdom), J. Underwood (Cardiff, United Kingdom), A. Hicks (Portsmouth, United Kingdom), D. Dosanjh (Birmingham, United Kingdom), B. Sage (Inverness, United Kingdom), D. Dhasmana (Kirkcaldy, United Kingdom), M. Spears (Dundee, United Kingdom), A. Thompson (Sheffield, United Kingdom), C. Brightling (Leicester, United Kingdom), A. Smith (Wishaw, United Kingdom), M. Patel (Wishaw, United Kingdom), J. George (Dundee, United Kingdom), A. Condliffe (Sheffield, United Kingdom), A. Shoemark (Dundee, United Kingdom), G. Maclennan (Aberdeen, United Kingdom), J. Chalmers (Dundee, United Kingdom)
Source: International Congress 2022 – ALERT 3: COVID and interstitial lung diseases??
Session: ALERT 3: COVID and interstitial lung diseases??
Session type: Clinical trials session
Number: 2883
  
Rating: 
You must login to grade this presentation.
Share or cite this content
Citations should be made in the following way:
H. Keir (Dundee, United Kingdom), M. Long (Dundee, United Kingdom), H. Abo-Leyah (Dundee, United Kingdom), Y. Giam (Dundee, United Kingdom), T. Vadiveloo (Aberdeen, United Kingdom), T. Pembridge (Dundee, United Kingdom), R. Hull (Sheffield, United Kingdom), L. Delgado (Dundee, United Kingdom), M. Band (Dundee, United Kingdom), F. Mclaren-Neil (Dundee, United Kingdom), S. Adamson (Dundee, United Kingdom), E. Lahnsteiner (Dundee, United Kingdom), A. Gilmour (Dundee, United Kingdom), C. Hughes (Dundee, United Kingdom), B. New (Dundee, United Kingdom), D. Connell (Dundee, United Kingdom), R. Dowey (Sheffield, United Kingdom), H. Turton (Sheffield, United Kingdom), H. Richardson (Dundee, United Kingdom), D. Cassidy (Dundee, United Kingdom), J. Cooper (Aberdeen, United Kingdom), J. Suntharalingam (Bath, United Kingdom), L. Diwakar (Stoke-on-Trent, United Kingdom), P. Russell (Harlow, United Kingdom), J. Underwood (Cardiff, United Kingdom), A. Hicks (Portsmouth, United Kingdom), D. Dosanjh (Birmingham, United Kingdom), B. Sage (Inverness, United Kingdom), D. Dhasmana (Kirkcaldy, United Kingdom), M. Spears (Dundee, United Kingdom), A. Thompson (Sheffield, United Kingdom), C. Brightling (Leicester, United Kingdom), A. Smith (Wishaw, United Kingdom), M. Patel (Wishaw, United Kingdom), J. George (Dundee, United Kingdom), A. Condliffe (Sheffield, United Kingdom), A. Shoemark (Dundee, United Kingdom), G. Maclennan (Aberdeen, United Kingdom), J. Chalmers (Dundee, United Kingdom). Dipeptidyl Peptidase-1 Inhibition in Patients Hospitalized with COVID-19: a Multicentre Randomized Double-Blind Placebo Controlled Trial. 2883
You must login to share this Presentation/Article on Twitter, Facebook, LinkedIn or by email.
Member's Comments
Related content which might interest you:
|
|